Correlation of Dopaminergic Denervation and the Progression of Autonomic Dysfunctions in Different Clinical Subtypes of Parkinson’s Disease
Table 1
Baseline patient characteristics.
TD subtype (n = 221)
Indeterminate subtype (n = 29)
PIGD subtype (n = 75)
value
Age at PD onset (years)
61.2 ± 9.6
62.2 ± 9.1
60.5 ± 10.1
0.78
Gender (male : female)
144 : 78
23 : 6
48 : 17
0.16
Weight (kg)
82.2 ± 17.8
82.8 ± 12.7
79.5 ± 16.6
0.44
Duration of symptoms until study enrolment (months)
61.7 ± 58.4a)
73.3 ± 53.8a)
46.6 ± 30.8b)
<0.05
Hoehn and Yahr staging at baseline
1.5 ± 0.5a)
1.9 ± 0.4b)
1.6 ± 0.5a)
<0.001
MDS-UPDRS Part I score at baseline
2.2 ± 1.6
2.1 ± 1.2
2.7 ± 2.0
0.08
MDS-UPDRS Part II score at baseline
5.9 ± 3.6a)
9.4 ± 4.5b)
8.0 ± 4.3b)
<0.001
MDS-UPDRS Part III score at baseline
20.1 ± 8.6a)
25.2 ± 8.9b)
20.1 ± 8.0a)
<0.05
SCOPA-AUT score
8.4 ± 5.8a)
10.6 ± 5.0b)
9.4 ± 5.9
<0.05
SBR, putamen
0.7 ± 0.2a)
0.6 ± 0.1b)
0.6 ± 0.2b)
<0.05
SBR, caudate
1.9 ± 0.5a)
1.6 ± 0.3b)
1.7 ± 0.5b)
<0.01
Use of dopamine agonist (%)
56.5
51.7
61
0.63
Average LEDD at 48 months (g)
379.0 ± 245.5
401.9 ± 179.6
359.1 ± 198.5
0.52
For a particular variable, values with different superscripts indicate a statistically significant difference. PD: Parkinson’s disease; MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; SCOPA-AUT: Scale for Outcomes in Parkinson’s Disease-Autonomic; SBR: Specific binding ratio; LEDD: levodopa equivalent dose.
